Deutsche Bank Analysts Give Novartis (VTX:NOVN) a CHF 90 Price Target

Deutsche Bank set a CHF 90 price objective on Novartis (VTX:NOVN) in a research note released on Monday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

NOVN has been the topic of a number of other research reports. Barclays set a CHF 80 target price on Novartis and gave the company a sell rating in a research note on Thursday, September 5th. UBS Group set a CHF 90 target price on Novartis and gave the stock a neutral rating in a research report on Tuesday, July 30th. HSBC set a CHF 88 price target on Novartis and gave the stock a neutral rating in a research note on Monday, July 22nd. Morgan Stanley set a CHF 83 price target on Novartis and gave the company a sell rating in a report on Thursday, May 30th. Finally, JPMorgan Chase & Co. set a CHF 82 price target on Novartis and gave the company a sell rating in a research note on Wednesday, August 28th. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the stock. Novartis has an average rating of Hold and an average price target of CHF 90.92.

Novartis has a 1-year low of CHF 72.45 and a 1-year high of CHF 88.30.

Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Read More: What is an inverted yield curve?

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.